Press releases

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.

The new facility will cover an area of 6,400 sqm (69,000 sqft), and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The expanded facility will adhere to current good manufacturing practices (cGMP) and fulfilling both EU and US GMP requirements ensuring the delivery of safe, reliable, and compliant biopharmaceutical products.

Finnish Bioindustries FIB appoints Alexandra Peth as Managing Director

Finnish Bioindustries long-term director Carmela Kantor-Aaltonen is retiring in August 2023. M.Sc. Alexandra Peth has been appointed as her successor, in a  Managing Director role for Finnish Bioindustries starting on August 1st, 2023.

Alexandra currently works as Senior Advisor of innovation and finance at Chemical Industry Federation of Finland. She will continue working for Chemical Industry Federation of Finland beside her role as Managing Director of Finnish Bioindustries.

Organon to acquire Forendo Pharma – acquisition adds pipeline of candidates targeting novel treatments in women’s health

JERSEY CITY, N.J. & TURKU, FINLAND – Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor in early clinical development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Endometriosis is a common and chronic condition that affects up to 1 in 10 women of reproductive age, causes abdominal pain and is associated with infertility.

  1. AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
  2. Quest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare Diseases
  3. Blueprint Genetics expands in North America by building a new CLIA/CAP NGS facility in Seattle
  4. DelSiTech Ltd Receives Significant Funding for Developing Long-Acting Injectables for contraceptives and HIV antivirals development by the Bill & Melinda Gates Foundation
  5. Helsinki Biobank and Fimmic Introduce a Unique One Access Service for Biomedical Research
  6. Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial
  7. Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
  8. Fimmic closes investment round to digitalize cancer diagnostics
  9. Faron Pharmaceuticals Oy Intention to Float on AIM
  10. Innomedica to open new office in Switzerland
  11. FIT Biotech’s Initial Public Offering Completed Successfully
  12. BioFinland prize to Biovian Oy
  13. Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men
  14. Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102
  15. Promising new treatment for life threatening acute respiratory distress syndrome (ARDS)
  16. KU Leuven and FIT Biotech enter into a worldwide license and collaboration agreement for the development of novel immunotherapeutics
  17. Neste Jacobs and Roal Sign a Contract to Expand Enzyme Production Plant
  18. BioFinland 2013 prize to Glykos Finland Ltd
  19. Culminatum Innovation and Diaceutics Collaborate to Provide Expert Training to Leading Finnish Researchers on Commercializing Biomarkers for Personalized Medicine
  20. Innomedica and CMC Biologics into strategic agreement for Japan market
  21. Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries
  22. Faron and Maruishi Sign Traumakine-program License Agreement
  23. Rentschler to manufacture Faron product Traumakine®
  24. Change of management in Novamass Ltd
  25. Innomedica Expands in UK – Dr Jim Phillips Joins the Team

FINNISH BIOINDUSTRIES FIB
Eteläranta 10, FI-00131 Helsinki
+358 50 404 5166